Cartesian Therapeutics/$RNAC

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Cartesian Therapeutics

Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.

Ticker

$RNAC
Trading on

Industry

Biotechnology

Employees

66

ISIN

US8162123025

RNAC Metrics

BasicAdvanced
$248M
-
-$1.73
-
-

What the Analysts think about RNAC

Analyst ratings (Buy, Hold, Sell) for Cartesian Therapeutics stock.

RNAC Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

RNAC Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $RNAC

Sign up or log in to buy
Capital at risk
Market openLow-cap

Upcoming events

No upcoming events
FAQs